Patents by Inventor Geoff G. Z. Zhang

Geoff G. Z. Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ABT-263 crystalline forms
    Patent number: 8362014
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: January 29, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
  • Salt of ABT-263 and solid-state forms thereof
    Patent number: 8362013
    Abstract: ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: January 29, 2013
    Assignee: AbbVie Inc.
    Inventors: Thomas Borchardt, Paul Brackemeyer, Nathaniel Catron, Rodger Henry, Xiaochun Lou, Matthew Ravn, Geoff G. Z. Zhang, Deliang Zhou
  • Crystal forms of kinase inhibitors
    Patent number: 8357804
    Abstract: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: January 22, 2013
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF
    Publication number: 20130018101
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Inventors: Russell Drew Cink, Joseph B. Paterson, JR., Yi Gao, Geoff G. Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
  • Azaadamantane derivatives and methods of use
    Patent number: 8314119
    Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: November 20, 2012
    Assignee: AbbVie Inc.
    Inventors: Michael R. Schrimpf, Diana L. Nersesian, Kevin B. Sippy, Jianguo Ji, Tao Li, Marc Scanio, Lei Shi, Chih-Hung Lee, William H. Bunnelle, Geoff G. Z. Zhang, Paul J. Brackemeyer, Shuang Chen, Rodger F. Henry
  • Preparation of pyridonecarboxylic acid antibacterials
    Patent number: 8299254
    Abstract: A process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, and therapeutically acceptable salts thereof, and intermediates used in the process are disclosed.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: October 30, 2012
    Assignee: Abbott Laboratories
    Inventors: Anthony Haight, David M. Barnes, Geoff G. Z. Zhang
  • Salt and crystalline forms thereof of a drug
    Patent number: 8273892
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: September 25, 2012
    Assignee: Abbott Laboratories
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Salt and crystalline forms thereof of a drug
    Patent number: 8252813
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: August 28, 2012
    Assignee: Abbott Laboratories
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Crystal Forms of Kinase Inhibitors
    Publication number: 20120202844
    Abstract: Citrate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Application
    Filed: June 8, 2011
    Publication date: August 9, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G. Z. Zhang, Doug H. Hoffman, Jonathan Miller
  • Crystalline Forms of Kinase Inhibitors
    Publication number: 20120203002
    Abstract: Salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Application
    Filed: June 8, 2011
    Publication date: August 9, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • Crystal Forms of Kinase Inhibitors
    Publication number: 20120149726
    Abstract: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
    Type: Application
    Filed: June 9, 2011
    Publication date: June 14, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
  • Anti-infective agents and uses thereof
    Patent number: 8188104
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: May 29, 2012
    Assignee: Abbott Laboratories
    Inventors: Charles A. Flengte, Douglas K. Hutchinson, David A. Betebenner, David A. DeGoey, Pamela L. Donner, Warren M. Kati, Allan C. Krueger, Dachun Liu, Yaya Liu, Kenton L. Longenecker, Clarence J. Maring, Christopher E. Motter, John K. Pratt, John T. Randolph, Todd W. Rockway, Kent D. Stewart, Rolf Wagner, Shuang Chen, Yi Gao, Xiaochun Lou, Geoff G. Z. Zhang
  • Anti-infective agents and uses thereof
    Patent number: 8178548
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: May 15, 2012
    Assignee: Abbott Laboratories
    Inventors: Pamela L. Donner, John T. Randolph, Allan C. Krueger, David A. Betebenner, Douglas K. Hutchinson, Dachun Liu, Yaya Liu, Kenton L. Longenecker, Clarence J. Maring, John K. Pratt, Todd W. Rockway, Kent D. Stewart, Rolf Wagner, Shuang Chen, Yi Gao, John E. Hengeveld, Rodger F. Henry, Xiaochun Lou, Geoff G. Z. Zhang
  • ABT-263 CRYSTALLINE FORMS
    Publication number: 20110294811
    Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Application
    Filed: July 28, 2011
    Publication date: December 1, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
  • (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
    Patent number: 7902371
    Abstract: The present invention relates to the salt (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate and to methods of preparing the salt.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: March 8, 2011
    Assignee: Abbott Laboratories
    Inventors: Gregory S. Wayne, Sean M. Mellican, Geoff G. Z. Zhang, David R. Willcox, Jeffrey M. Breting
  • STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER
    Publication number: 20100278905
    Abstract: An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Application
    Filed: April 29, 2010
    Publication date: November 4, 2010
    Inventors: Nathaniel Catron, Michael G. Fickes, Cristina M. Fischer, Anthony R. Haight, Katherine Heemstra, Yeshwant D. Sanzgiri, Eric A. Schmitt, Ping Tong, Geoff G. Z. Zhang, Deliang Zhou
  • Salt and crystalline forms thereof of a drug
    Patent number: 7728143
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: June 1, 2010
    Assignee: Abbott Laboratories
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF
    Publication number: 20090263477
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Application
    Filed: June 23, 2009
    Publication date: October 22, 2009
    Applicants: ABBOTT LABORATORIES, FOURNIER LABORATORIES IRELAND LTD
    Inventors: Russell D. Cink, Joseph B. Paterson, Yi Gao, Geoff G. Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
  • Preparation of pyridonecarboxylic acid antibacterials
    Patent number: 7576216
    Abstract: A process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, and therapeutically acceptable salts thereof, and intermediates used in the process are disclosed.
    Type: Grant
    Filed: July 28, 2005
    Date of Patent: August 18, 2009
    Assignee: Abbott Laboratories
    Inventors: Anthony Haight, David M. Barnes, Geoff G. Z. Zhang
  • (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
    Patent number: 7538226
    Abstract: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: May 26, 2009
    Assignee: Abbott Laboratories
    Inventors: Michael J. Buckley, Jianguo Ji, Geoff G. Z. Zhang, Rodger F. Henry, Weili W. Wang, Gregory S. Wayne, Wenke Li, Timothy B. Towne, Steven J. Wittenberger, Steven M. Hannick, Brian J. Kotecki, Bryan S. Macri, Timothy A. Robbins